Macclesfield, United Kingdom

Nigel N Petter

This inventor holds 1 USPTO granted patent. Top assignee: Imperial Chemical Industries Limited. Active years: 1978.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1978

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Nigel N Petter

Introduction

Nigel N Petter is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel polypeptides with therapeutic applications. His work focuses on creating compounds that possess both analgesic and sedative properties.

Latest Patents

Nigel N Petter holds 1 patent for his invention titled "Analgesic and Sedative Polypeptides." This patent discloses novel polypeptides that exhibit analgesic and sedative activity. The invention includes processes for their manufacture and compositions containing these polypeptides, showcasing his innovative approach to pain management and sedation.

Career Highlights

Throughout his career, Nigel has been associated with Imperial Chemical Industries Limited, a prominent company in the chemical and pharmaceutical sectors. His work at this organization has allowed him to explore and develop new therapeutic agents that can improve patient care.

Collaborations

Nigel has collaborated with esteemed colleagues such as Anand Swaroop Dutta and James J Gormley. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the pharmaceutical industry.

Conclusion

Nigel N Petter's contributions to the field of pharmaceuticals through his innovative polypeptides demonstrate his commitment to advancing medical science. His work continues to impact the development of effective analgesic and sedative therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…